Modern Care Journal

Published by: Kowsar
Crossmark

Can Multi-Stage Recombinant Fusion Proteins be Considered as Reliable Vaccines Against Tuberculosis? A Letter to the Editor

Masoud Keikha ORCID 1 and Mohsen Karbalaei 2 , *
Authors Information
1 Department of Microbiology and Virology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
2 Department of Microbiology and Virology, School of Medicine, Jiroft University of Medical Sciences, Jiroft, Iran
Article information
  • Modern Care Journal: April 30, 2019, 16 (2); e91493
  • Published Online: May 15, 2019
  • Article Type: Letter
  • Received: March 11, 2019
  • Revised: April 30, 2019
  • Accepted: May 3, 2019
  • DOI: 10.5812/modernc.91493

To Cite: Keikha M, Karbalaei M. Can Multi-Stage Recombinant Fusion Proteins be Considered as Reliable Vaccines Against Tuberculosis? A Letter to the Editor, Mod Care J. 2019 ; 16(2):e91493. doi: 10.5812/modernc.91493.

Copyright © 2019, Modern Care Journal. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
Footnotes
References
  • 1. World Health Organization. Global tuberculosis report 2016. World Health Organization; 2016.
  • 2. World Health Organization. Global tuberculosis report 2017. World Health Organization; 2017.
  • 3. Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis infection. N Engl J Med. 2015;372(22):2127-35. doi: 10.1056/NEJMra1405427. [PubMed: 26017823].
  • 4. Khoshnood S, Heidary M, Haeili M, Drancourt M, Darban-Sarokhalil D, Nasiri MJ, et al. Novel vaccine candidates against Mycobacterium tuberculosis. Int J Biol Macromol. 2018;120(Pt A):180-8. doi: 10.1016/j.ijbiomac.2018.08.037. [PubMed: 30098365].
  • 5. Khademi F, Derakhshan M, Yousefi-Avarvand A, Tafaghodi M, Soleimanpour S. Multi-stage subunit vaccines against Mycobacterium tuberculosis: An alternative to the BCG vaccine or a BCG-prime boost? Expert Rev Vaccines. 2018;17(1):31-44. doi: 10.1080/14760584.2018.1406309. [PubMed: 29148853].
  • 6. Andersen P, Kaufmann SH. Novel vaccination strategies against tuberculosis. Cold Spring Harb Perspect Med. 2014;4(6). doi: 10.1101/cshperspect.a018523. [PubMed: 24890836]. [PubMed Central: PMC4031959].
  • 7. Kaufmann SH. Tuberculosis vaccines: Time to think about the next generation. Semin Immunol. 2013;25(2):172-81. doi: 10.1016/j.smim.2013.04.006. [PubMed: 23706597].
  • 8. Lindenstrom T, Agger EM, Korsholm KS, Darrah PA, Aagaard C, Seder RA, et al. Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J Immunol. 2009;182(12):8047-55. doi: 10.4049/jimmunol.0801592. [PubMed: 19494330].
  • 9. Aagaard C, Hoang T, Dietrich J, Cardona PJ, Izzo A, Dolganov G, et al. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med. 2011;17(2):189-94. doi: 10.1038/nm.2285. [PubMed: 21258338].
  • 10. Karbalaei Zadeh Babaki M, Soleimanpour S, Rezaee SA. Antigen 85 complex as a powerful Mycobacterium tuberculosis immunogene: Biology, immune-pathogenicity, applications in diagnosis, and vaccine design. Microb Pathog. 2017;112:20-9. doi: 10.1016/j.micpath.2017.08.040. [PubMed: 28942172].
  • 11. Kaufmann SH, Weiner J, von Reyn CF. Novel approaches to tuberculosis vaccine development. Int J Infect Dis. 2017;56:263-7. doi: 10.1016/j.ijid.2016.10.018. [PubMed: 27816661].
  • 12. Reither K, Katsoulis L, Beattie T, Gardiner N, Lenz N, Said K, et al. Safety and immunogenicity of H1/IC31(R), an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells/mm3: A phase II, multi-centre, double-blind, randomized, placebo-controlled trial. PLoS One. 2014;9(12). e114602. doi: 10.1371/journal.pone.0114602. [PubMed: 25490675]. [PubMed Central: PMC4260867].
  • 13. Keikha M, Moghim S, Fazeli H, Nasr-Esfahani B. The fusion multistage synthetic peptides as the best candidates for new tuberculosis vaccine. Adv Biomed Res. 2018;7:122. doi: 10.4103/abr.abr_116_18. [PubMed: 30211135]. [PubMed Central: PMC6124223].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments